已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Abstract 1794: The HSP90 inhibitor, AT13387, combined with erlotinib improves response in EGFR-driven xenograft models of NSCLC

作者
Tomoko Smyth,Jon Lewis,Keisha Hearn,Neil T. Thompson,John C. Lyons,Nicola G. Wallis
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:74 (19_Supplement): 1794-1794
标识
DOI:10.1158/1538-7445.am2014-1794
摘要

Abstract Background: Although Epidermal Growth Factor Receptor (EGFR)-driven non-small cell lung cancer (NSCLC) can be successfully treated with EGFR inhibitors such as erlotinib, relapse is common due to the development of resistance. Methods to improve response and delay resistance are therefore of value. Inhibition of the chaperone, HSP90, leads to the depletion of many client proteins, including EGFR, and has the capacity to simultaneously affect many signalling pathways, offering an alternative strategy for targeting EGFR-driven disease. AT13387 is a potent, second generation HSP90 inhibitor currently being tested in Phase II clinical trials. Here we investigated the effects of combining AT13387 and erlotinib in models of EGFR-driven NSCLC. Results: AT13387 single-agent treatment was effective in EGFR-driven NSCLC xenograft models, significantly inhibiting tumor growth of both HCC827 and NCI-H1650 xenograft tumors when dosed once weekly (see table). As expected, treatment with erlotinib caused significant tumor regression in all HCC827 tumors, but was less effective in the NCI-H1650 model; its PTEN status conferring a reduction in sensitivity. However, combination of AT13387 with erlotinib led to a further enhancement of tumor growth inhibition over either of the monotherapies in both of these models. All HCC827 tumors treated with the combination regressed further (by at least 80%), and regression was also now observed in all NCI-H1650 tumors. These data demonstrate that combination with AT13387 has the potential to increase response, despite the differing initial sensitivities to erlotinib of these models. The combination was well tolerated. Effects of AT13387 and erlotinib on EGFR-driven xenograftsCell lineGenetic BackgroundT/C(Median RTV, treated / control)AT1338755 mg/kg ip 1qwErlotinib12.5 mg/kg po qdCombinationHCC827(Day 32)EGFR Del E746_A75026%17%(47% regression)6%(84% regression)NCI-H1650(Day 31)EGFR Del E746_A750/PTEN del35%36%6%(50% regression) Conclusions: AT13387 was shown to improve response when combined with erlotinib in EGFR-driven xenograft models. These data suggest that there is therapeutic potential in an upfront combination of an HSP90 inhibitor, such as AT13387, with erlotinib and support clinical investigation of such a combination. Citation Format: Tomoko Smyth, Jon Lewis, Keisha Hearn, Neil Thompson, John Lyons, Nicola G. Wallis. The HSP90 inhibitor, AT13387, combined with erlotinib improves response in EGFR-driven xenograft models of NSCLC. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1794. doi:10.1158/1538-7445.AM2014-1794

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
醋溜茄子完成签到,获得积分10
1秒前
邢绿凝发布了新的文献求助10
1秒前
2秒前
u300843发布了新的文献求助60
2秒前
lww完成签到 ,获得积分10
2秒前
qq完成签到,获得积分10
3秒前
Zzyj完成签到 ,获得积分10
4秒前
sally_5202完成签到,获得积分10
4秒前
01259完成签到 ,获得积分0
4秒前
4秒前
Tim完成签到,获得积分10
4秒前
舒适思松完成签到 ,获得积分10
4秒前
雾散完成签到 ,获得积分10
5秒前
5秒前
哈哈哈完成签到 ,获得积分10
6秒前
3921337477的应助被u553973采纳,获得60
6秒前
富婆丹完成签到 ,获得积分10
6秒前
溜了溜了完成签到 ,获得积分10
6秒前
我看看怎么个事的应助被somnia采纳,获得30
6秒前
hally发布了新的文献求助10
7秒前
幽默棒球完成签到,获得积分10
7秒前
8秒前
学霸业的应助被answer答案采纳,获得10
8秒前
糖炒板栗完成签到,获得积分10
8秒前
9秒前
邢绿凝发布了新的文献求助10
9秒前
追风少年完成签到,获得积分10
9秒前
幸福幸福完成签到 ,获得积分10
9秒前
沉疴能自痊完成签到 ,获得积分10
10秒前
俭朴山灵完成签到 ,获得积分0
10秒前
hfq完成签到 ,获得积分10
10秒前
alex的应助被忐忑的元彤采纳,获得10
10秒前
皮皮虾完成签到 ,获得积分10
10秒前
晔晔珺璟完成签到 ,获得积分10
10秒前
龙九局完成签到 ,获得积分10
11秒前
深情的白柏完成签到 ,获得积分10
11秒前
齐天大圣完成签到,获得积分10
11秒前
Hello的应助被sodiiai采纳,获得10
11秒前
可可完成签到 ,获得积分10
12秒前
8o7XJ7完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184764
求助须知:如何正确求助?哪些是违规求助? 9573733
关于积分的说明 21832921
捐赠科研通 7782115
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481067

今日热心研友

3921337477
2 120
Maestro_S
1 30
我看看怎么个事
30
学霸业
1 10
注:热心度 = 本日应助数 + 本日被采纳获取积分÷10